P PRIMESTOCKFINDER.COM

ATX Shares Amplia Therapeutics Limited

ASX · ASX
$0.08 -1.28% Prices as of close 2026-10-27

Last in our picks 2026-10-26 — not in the current list; analysis below is from that screen

Fibrosis and oncology programs offer meaningful optionality if clinical milestones improve investor confidence.

Signal breakdown

  • ▸Clinical development milestones
  • ▾Below 50-day MA (-36.04%)
  • ▾Near 52-week low (0.5% of range)

Is ATX a buy right now?

Trend: ATX is trading below the 50-day average (-35.83%), RSI 57 — neutral momentum, with a 3-month return of -38.40%.

Valuation & quality: Amplia Therapeutics Limited trades on forward P/E -11.0, price-to-book 1.00; fundamentals show net margin -160.9%, return on equity -25.5%, revenue growth -9.1% year on year.

Analyst consensus: 1 analysts have a mean 12-month price target of A$0.42 (+445.5% vs the last close; range A$0.42 – A$0.42), consensus rating “none”.

Our screen: WATCH (score 0) — Fibrosis and oncology programs offer meaningful optionality if clinical milestones improve investor confidence.

Computed from end-of-day data; not personal advice.

12-month price chart

0.26 0.08 FebMarAprMayJunJulAugSepOct
Daily close, 2026-02-08 → 2026-10-27 (AUD). Range 0.08 – 0.26.

Monthly returns

Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
+116.70%-42.30%-6.70%+0.00%-7.10%+7.70%-14.30%-33.30%

Fundamentals

Market cap
$39.5M
P/E (ttm)
-11.0
Forward P/E
-11.0
EPS (ttm)
$-0.02
Price / book
1.00
Beta
-0.33
Net margin
-160.9%
ROE
-25.5%
Revenue growth
-9.1%
Revenue (ttm)
$4.8M
Free cash flow
$-6,482,243
Debt / equity
1%
52-wk range
$0.08 – $0.28
Volume
69,680
Avg volume (3m)
1,097,492

Analyst price target

Mean target
$0.42
Low
$0.42
High
$0.42
Analysts
1
Consensus
NONE

Technical signals

RSI (14)
57.3
vs 50-day MA
-35.83%
1-mo return
-35.83%
3-mo return
-38.40%
Volume z-score
0.00

About Amplia Therapeutics Limited

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.

Sector: Healthcare · Industry: Biotechnology · Australia · Website

Related Biotech picks

CSL.AXCSL LimitedMSB.AXMesoblast LimitedIMR.AXImricor Medical SystemSLD.AXSaluda Medical, Inc.NUZ.AXNeurizon Therapeutics NEU.AXNeuren PharmaceuticalsDXB.AXDimerix LimitedNYR.AXNyrada Inc.

Browse: all ASX stocks · Biotech picks · today's movers

General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.